Sutherland D E, Moudry K C
Pancreas. 1987;2(4):473-88.
From December 1966 to October 1986, 1001 pancreas transplants in 932 diabetic patients were reported to the International Pancreas Transplant Registry. One year actuarial graft function (insulin-independent) and recipient survival rates for all cases were 35% and 75%, respectively. In an analysis by era of 1966-77 (n = 64), 1978-82 (n = 201), 1983-84 (n = 298) and 1985-86 (n = 438) cases, 1 year graft function rates were 3, 21, 39, and 44% and recipient survival rates were 42, 72, 76, and 83, respectively (p less than 0.05 all comparisons, except 1983-84 vs. 1985-86). In an analysis of 1983-1986 cases only (n = 736), the overall 1 year graft function and patient survival rates were 42 and 79%, respectively. During this period, graft functional survival rates were similar (p greater than 0.8) for the most common duct management methods, 43% for duct injection (n = 254), 42% for enteric drainage (n = 254), and 47% for bladder drainage (n = 196) at 1 year. Graft function rates were also similar (p greater than 0.6) for whole (n = 280) and segmental (n = 456) pancreas transplants (41 vs. 42% at 1 year). Functional survival rates according to duration of preservation for grafts stored less than 6 h (n = 460), 6-12 h (n = 146) and greater than or equal to 12 h (n = 52) were 46, 39, and 30% at 1 year, and the difference was significant for the less than 6 vs. the 6-12 h preservation time (p = 0.023). Graft functional survival rates were significantly higher (p less than 0.05) in recipients who received azathioprine (AZA) and cyclosporine (CSA) in combination (n = 408) than in those who received CSA without azathioprine (n = 262) or AZA without cyclosporine, (n = 56), with 1 year graft functional survival rates of 47, 38, and 34%, respectively. For technically successful grafts, the functional survival rates were also significantly higher (p less than 0.05) in recipients treated with CSA + AZA (n = 309) than in those who received CSA without azathioprine (n = 186) or AZA without cyclosporine (n = 44), with 1 year function rates of 63, 53, and 41%, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)
1966年12月至1986年10月期间，932例糖尿病患者接受了1001例胰腺移植手术，并向国际胰腺移植登记处进行了报告。所有病例的一年期移植功能（不依赖胰岛素）和受者生存率分别为35%和75%。对1966 - 1977年（n = 64）、1978 - 1982年（n = 201）、1983 - 1984年（n = 298）以及1985 - 1986年（n = 438）各时期的病例分析显示，一年期移植功能率分别为3%、21%、39%和44%，受者生存率分别为42%、72%、76%和83%（除1983 - 1984年与1985 - 1986年比较外，所有比较p值均小于0.05）。仅对1983 - 1986年的病例（n = 736）进行分析，总体一年期移植功能和患者生存率分别为42%和79%。在此期间，最常见的导管处理方法在一年期时移植功能生存率相似（p值大于0.8），导管注射法（n = 254）为43%，肠道引流法（n = 254）为42%，膀胱引流法（n = 196）为47%。全胰腺移植（n = 280）和节段性胰腺移植（n = 456）的移植功能率也相似（p值大于0.6）（一年期时分别为41%和42%）。对于保存时间小于6小时（n = 460）、6 - 12小时（n = 146）以及大于或等于12小时（n = 52）的移植物，一年期时根据保存时间的功能生存率分别为46%、39%和30%，保存时间小于6小时与6 - 12小时之间差异具有统计学意义（p = 0.023）。联合使用硫唑嘌呤（AZA）和环孢素（CSA）的受者（n = 408）的移植功能生存率显著高于单独使用CSA（n = 262）或单独使用AZA（n = 56）的受者（p值小于0.05），一年期移植功能生存率分别为47%、38%和34%。对于技术成功的移植物，接受CSA + AZA治疗的受者（n = 309）的功能生存率也显著高于单独使用CSA（n = 186）或单独使用AZA（n = 44）的受者（p值小于0.05），一年期功能率分别为63%、53%和41%。（摘要截选至400字）
